Biological agents for giant cell arteritis: treat to target.


In a case series published in the Annals of the Rheumatic Diseases, Conway et al reported a significant steroid-sparing effect of ustekinumab (monoclonal antibody to interleukin (IL)-12 and IL-23) in 14 patients with giant cell arteritis (GCA). Recently, Ferfar et al summarised current evidence showing the efficacy of tocilizumab and abatacept in patients… (More)
DOI: 10.1136/annrheumdis-2016-210061


1 Figure or Table